Scholarlink

<p>PM<sub>2.5</sub>-induced lung injury challenges poultry health with limited treatments. Mogroside’s unique therapeutic impact on pulmonary inflammation may involve modulating the lung microbiome, which influences immune function and respiratory health. We first demonstrated that mogroside (MG) supplementation improved growth performance and mitigated PM<sub>2.5</sub>-induced alveolar damage, inflammatory cytokine release, and Th17 differentiation (<i>p</i> &lt; 0.05). MG increased the abundance of beneficial bacteria, particularly <i>Lactobacillus</i> (<i>p</i> &lt; 0.01). Notably, MG IIE accumulated in lung tissues and bronchoalveolar lavage fluid (BALF). To further clarify the role of microbe–metabolite interactions, BALF from MG-treated broilers was transplanted. Only complete BALF containing both MG and microbiota significantly alleviated fibrosis (<i>p</i> &lt; 0.05), reshaped lung microbial composition, and modulated metabolites such as taurine and lactic acid. Microbiome analysis identified <i>Sphingomonas</i> as a key taxon enriched in MG-BALF, strongly correlated with protective metabolites. In vitro assays confirmed that <i>Sphingomonas</i> degraded MG IIE into mogrol via β-glucosidase activity. Finally, a Calu-3–Jurkat T lymphocytes co-culture model revealed that MG IIE, particularly in combination with <i>Sphingomonas</i> metabolites, preserved barrier integrity, suppressed NF-κB phosphorylation, reduced ROS, and inhibited Th17-associated cytokine expression. Collectively, MG IIE and its <i>Sphingomonas</i>-mediated metabolites form a lung microbiota–metabolite–host axis that protects against PM<sub>2.5</sub>-induced pulmonary injury.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lung microbiota-mediated biotransformation of mogroside preserves pulmonary barrier integrity and attenuates PM2.5-induced inflammation via NF-κB–Th17 modulations

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月5日

查看全文
  • Kai Wang,
  • Yuan Li,
  • Cuiguang Li,
  • Mohammed Kahiel,
  • Kentaro Nagaoka,
  • Dan Shen,
  • Chunmei Li

摘要

PM2.5-induced lung injury challenges poultry health with limited treatments. Mogroside’s unique therapeutic impact on pulmonary inflammation may involve modulating the lung microbiome, which influences immune function and respiratory health. We first demonstrated that mogroside (MG) supplementation improved growth performance and mitigated PM2.5-induced alveolar damage, inflammatory cytokine release, and Th17 differentiation (p < 0.05). MG increased the abundance of beneficial bacteria, particularly Lactobacillus (p < 0.01). Notably, MG IIE accumulated in lung tissues and bronchoalveolar lavage fluid (BALF). To further clarify the role of microbe–metabolite interactions, BALF from MG-treated broilers was transplanted. Only complete BALF containing both MG and microbiota significantly alleviated fibrosis (p < 0.05), reshaped lung microbial composition, and modulated metabolites such as taurine and lactic acid. Microbiome analysis identified Sphingomonas as a key taxon enriched in MG-BALF, strongly correlated with protective metabolites. In vitro assays confirmed that Sphingomonas degraded MG IIE into mogrol via β-glucosidase activity. Finally, a Calu-3–Jurkat T lymphocytes co-culture model revealed that MG IIE, particularly in combination with Sphingomonas metabolites, preserved barrier integrity, suppressed NF-κB phosphorylation, reduced ROS, and inhibited Th17-associated cytokine expression. Collectively, MG IIE and its Sphingomonas-mediated metabolites form a lung microbiota–metabolite–host axis that protects against PM2.5-induced pulmonary injury.